SCHEMBL2170502

SCHEMBL2170502

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1C(=O)c1ccc2ccccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 2/20 0.41
HPGD P15428 1/20 0.41
BCHE P06276 1/20 0.38
AKR1C1 Q04828 1/20 0.38
ENPP3 O14638 2/20 0.38
ALPL P05186 2/20 0.38
XIAP P98170 2/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
DRD4 P21917 1/20 0.37
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169090 0.86 USP2 (0.51) TSHRUSP2KMT2A
SCHEMBL13368960 0.85 RAB9A (0.40) RAB9ANPC1TSHRHPGDBCHE
SCHEMBL12474379 0.84 RAB9A (0.41) RAB9ANPC1TSHRHPGDBCHE
SCHEMBL2170075 0.83 CHRNA7 (0.41) TSHRHPGDKMT2A
SCHEMBL2169041 0.83 HPGD (0.41) RAB9AHPGDBCHEENPP3ALPL
SCHEMBL13368833 0.83 USP2 (0.38) USP2
SCHEMBL2168721 0.82 KMT2A (0.46) HPGDBCHEMEN1KMT2ACES2
SCHEMBL2169195 0.82 PKM (0.40) RAB9AHPGDENPP3ALPLXIAP
SCHEMBL13368830 0.82 USP2 (0.39) USP2
SCHEMBL2168658 0.82 PLA2G7 (0.41) TSHRHPGDUSP2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 RAB9A 2687/4885NPC1 155/4885TSHR 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.